Skip to content

Innovative Treatment for Scarred Vocal Cords by Local Injection of Autologous Stromal Vascular Fraction

Innovative Treatment for Scarred Vocal Cords by Local Injection of Autologous Stromal Vascular Fraction

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02622464
Enrollment
8
Registered
2015-12-04
Start date
2016-04-07
Completion date
2018-06-07
Last updated
2019-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dysphonia

Brief summary

Post-operative scarring on vocal cords is responsible for disorders of the vibration of the lining to the original dysphonia can be troublesome for the patient both in his private and professional life. There is no currently codified treatment for this type of situation and no therapeutic antifibrotic has been effective. Cell therapy is a promising new approach.After a liposuction and removing of mature adipocytes (40 to 60%), the remaining cells called stromal vascular fraction (SVF) could be isolated. SVF consists of a heterogeneous cell population including multipotent stem cells similar to mesenchymal stem cells present in bone marrow. The investigators hypothesis is that the trophic and antifibrotic properties of SVF could benefit patients with vocal cords scarring responsible for dysphonia.

Interventions

OTHERmicro injection of SVF in vocal cords

Sponsors

Assistance Publique Hopitaux De Marseille
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Vocal Difficulties felt as crippling (VHI \> 60/120) * Presence of scar hurts of the caused vocal cords is by the initial surgery (micro-laryngoscopy in suspension with or without laser) or by a congenital pathology of glottidis sulcus * Scar Aspect of vocal cords judged on a stroboscopic examination * Delay of at least 1 year with regard to the initial surgery

Exclusion criteria

* Patients refusing the speech therapy * Patients operated for a malignant lesion or in malignant potential serious dysplasia of the scar vocal cord * Contraindication in the anesthesia * Patients under anti-coagulants * Patients presenting disorders of the coagulation * Active infectious diseases

Design outcomes

Primary

MeasureTime frameDescription
feasibility of Stromal Vascular Fraction injection injected in vocal cords13 monthsfeasibility will be assessed by observation of the immediate volumizing effect on the edge free of the vocal cord appreciated on the video document
safety will be assessed by the absence of related events related to stromal vascular fraction injection injected in vocal cords13 monthssafety of Stromal Vascular Fraction injection injected in vocal cords

Secondary

MeasureTime frameDescription
efficiency of SVF injection for the treatment of scarred vocal cords with improved instrumental objective characteristics of the voice of the operated patients13 monthsefficiency of SVF injection will be assessed by visual analysis of the vocal cord vibration appreciated by vidéolaryngostroboscopy

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026